Pieris Pharmaceuticals Inc (PIRS)
Pieris Pharmaceuticals is a biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. Co.'s clinical pipeline includes elarekibep an inhaled IL-4Ra antagonist Anticalin protein to treat uncontrolled asthma, PRS-220, an inhaled CTGF antagonist to treat IPF and other forms for fibrotic lung disease, an immuno-oncology (IO) bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Co. has intellectual property rights directed to various aspects of its Anticalin technology platform, allowing for the development and improvement of both its platform and drug candidates. Co.'s development plans focus on its clinical and preclinical programs.
| Company Name: |
Pieris Pharmaceuticals Inc |
| Website: |
www.pieris.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding PIRS: |
1 |
| Total Market Value Held by ETFs: |
$143451 |
| Total Market Capitalization: |
$16.00M |
| % of Market Cap. Held by ETFs: |
0.90% |
|
|
April 19, 2024 • 9:31 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free PIRS Email Alerts:
